# Cognitive screening, in a conversation.

URL: https://nurevo.health/
Last updated: 2026-11-01

> Nurevo is the brand of Nurevo Technology Limited, company number SC892389.

Nurevo builds AI cognitive screening that turns a short, natural conversation into an explainable risk score for cognitive decline, helping clinicians decide who needs specialist assessment first.

In plain terms, Nurevo is building this screening for dementia.

Stage: Pre-seed. Working prototype of the data pipeline; preparing clinical validation.

## Four signal streams

- **Speech timing and voice.** Pauses, rate, rhythm and fluency. These parts of speech carry across languages.
- **Language.** Vocabulary, structure and coherence.
- **Facial movement.** Movement of the face during the conversation.
- **Background information.** Age, education and other context.

## How it works

Three steps, from a short conversation to an explainable risk score.

1. **A conversation.** A short guided conversation on a phone or laptop. It is low-burden, and it is designed to feel like a conversation rather than a test.
2. **Four streams.** Speech timing and voice, language, facial movement, and background information are analysed together.
3. **A risk score.** A cross-modal transformer combines the streams into one explainable risk score and shows which signals contributed most.

## Why this approach

- **Multimodal.** Multimodal rather than single-signal. Speech, language, facial movement and background information are analysed together.
- **Multilingual.** Built for multilingual populations from the start.
- **Explainable.** Explainable by design. The risk score shows which signals contributed most.

## Dementia

Specialist capacity is limited, so many people reach memory services late. Existing screening is slow, feels like a test, and was largely designed around one language and culture. The figures below are the published picture worldwide and in the UK.

### Worldwide

- 57 million people were living with dementia worldwide in 2021.
- Nearly 10 million new cases each year.
- More than 60% of people living with dementia live in low and middle income countries.

Source: [World Health Organization](https://www.who.int/news-room/fact-sheets/detail/dementia). Fact sheet updated 26 October 2026. The worldwide counts are for 2021.

### In the UK

- 982,000 people are estimated to be living with dementia in the UK.
- More than a third of people living with dementia in the UK have not been formally identified.
- 1.4 million people are expected to be living with dementia in the UK by 2040.

Source: [Alzheimer's Society](https://www.alzheimers.org.uk/about-us/policy-and-influencing/economic-impact-of-dementia). The three UK figures are taken from this page.

## Who it is for

Nurevo is being designed for organisations that need a low-burden way to prioritise who should be seen sooner.

- **Health systems and memory services.** Nurevo is being designed so health systems and memory services can prioritise referrals.
- **Primary care.** Nurevo is being designed for primary care, as a low-burden conversation that can offer an early signal before a specialist referral.
- **Care homes and community organisations.** Nurevo is being designed for care homes and community organisations, where a short conversation on a phone or laptop can be offered in the place where the person already is.
- **Pharmaceutical companies and research partners.** Nurevo is being designed for pharmaceutical companies and contract research organisations, to support recruitment and stratification for early-stage trials.

---

Nurevo Technology Limited is registered in Scotland, company number SC892389. Registered office: 89/63 Holyrood Road, Edinburgh, EH8 8BA.

Nurevo is a screening and triage tool in development. It is not a diagnostic device and is not currently available for clinical use.